Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

November 6, 2025

Leukogene Therapeutics gains FDA ODD status for M2T-CD33

Leukogene Therapeutics has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for M2T-CD33 (LTI-214), its immunotherapy candidate targeting acute myeloid leukaemia (AML).

Leukogene Therapeutics gains FDA ODD status for M2T-CD33